These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17325906)

  • 1. Encephalopathy with myoclonic jerks resulting from ceftazidime therapy: an under-recognized potential side-effect when treating febrile neutropenia.
    Martin MG
    Leuk Lymphoma; 2007 Feb; 48(2):413-4. PubMed ID: 17325906
    [No Abstract]   [Full Text] [Related]  

  • 2. [Myoclonic encephalopathy caused by bismuth salts. Efficacy of treatment with dimercaprol].
    Molina JA; Calandre L; Bermejo F; Posadas F; Fernández-Ortega JD
    Med Clin (Barc); 1989 Jun; 93(1):20-2. PubMed ID: 2770373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial neurotoxicity: an under-recognised cause of delirium.
    Moynan D; Maqbool E; de Barra E
    Acute Med; 2022; 21(2):115-116. PubMed ID: 35681187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of empiric monotherapy with ceftazidime for low-risk grade IV febrile neutropenia after cytotoxic chemotherapy in cancer patients.
    Chernobelski P; Lavrenkov K; Rimar D; Riesenberg K; Schlaeffer F; Ariad S; Mermershtain W
    Chemotherapy; 2006; 52(4):185-9. PubMed ID: 16675902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cefepime-induced encephalopathy in patients with renal failure].
    Martín Herrera C; Navarro M
    Nefrologia; 2009; 29(2):181. PubMed ID: 19396333
    [No Abstract]   [Full Text] [Related]  

  • 6. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
    N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myoclonic encephalopathy caused by bismuth].
    Nogué Xarau S; Sanz Gallén P
    Rev Clin Esp; 1990 Feb; 186(3):145. PubMed ID: 2356356
    [No Abstract]   [Full Text] [Related]  

  • 10. [Myoclonic encephalopathy in a patient treated with an excessive dose of buflomedil].
    Presse Med; 1983 May; 12(23):1492. PubMed ID: 6222351
    [No Abstract]   [Full Text] [Related]  

  • 11. [Myoclonic encephalopathy caused by isoniazid-hydantoin combination].
    Destee A; Verrier A; Gelez P; Warot P
    Lille Med; 1979 Jan; 24(1):41-5. PubMed ID: 431301
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical and electroencephalographic correlates in bismuth-induced myoclonic encephalopathy].
    Gastaut JL; Jouglard J
    Therapie; 1980; 35(3):293-6. PubMed ID: 7423414
    [No Abstract]   [Full Text] [Related]  

  • 13. Neurotoxicity associated with ceftazidime therapy in geriatric patients with renal dysfunction.
    Slaker RA; Danielson B
    Pharmacotherapy; 1991; 11(4):351-2. PubMed ID: 1923920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial.
    Feld R; DePauw B; Berman S; Keating A; Ho W
    J Clin Oncol; 2000 Nov; 18(21):3690-8. PubMed ID: 11054442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Piperacillin/tazobactam plus ceftazidime versus sulbactam/ampicillin plus aztreonam as empirical therapy for fever in severely neutropenic pediatric patients.
    Kobayashi R; Sato T; Nakajima M; Kaneda M; Iguchi A
    J Pediatr Hematol Oncol; 2009 Apr; 31(4):270-3. PubMed ID: 19346879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Polygraphic study of bismuth-induced myoclonic encephalopathy].
    Gastaut JL; Tassinari CA; Terzano G; Picornell I
    Rev Electroencephalogr Neurophysiol Clin; 1975; 5(3):295-302. PubMed ID: 1230925
    [No Abstract]   [Full Text] [Related]  

  • 17. Ceftazidime-induced encephalopathy in a patient with renal impairment.
    Douglas MA; Quandt CM; Stanley DA
    Arch Neurol; 1988 Sep; 45(9):936-7. PubMed ID: 3046579
    [No Abstract]   [Full Text] [Related]  

  • 18. [Myoclonic bismuth-induced encephalopathy. Case report (author's transl)].
    Loseke N; Retif J; Coune A; Soebert A; Molle L; D'haens J
    Acta Gastroenterol Belg; 1978; 41(1-2):72-80. PubMed ID: 665114
    [No Abstract]   [Full Text] [Related]  

  • 19. [Myoclonic encephalopathy due to ingestion of insoluble salts of bismuth].
    Cambier J; Dairou R
    Arch Fr Mal App Dig; 1975; 64(1):5-9. PubMed ID: 1164144
    [No Abstract]   [Full Text] [Related]  

  • 20. Cefuroxime-induced encephalopathy.
    Herishanu YO; Zlotnik M; Mostoslavsky M; Podgaietski M; Frisher S; Wirguin I
    Neurology; 1998 Jun; 50(6):1873-5. PubMed ID: 9633748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.